Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Update for July 26, 2022

7/25/2022

 
Regulatory Update
 
The FDA designated gedatolisib a Breakthrough Therapy for the treatment of HR+/HER2- metastatic breast cancer that has progressed during treatment with a CDK4/6 therapy and a non-steroidal aromatase inhibitor.
 
Acadia submitted an NDA for trofinetide for the treatment of Rett syndrome.
 

The United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) supports an expedited review of sabizabulin for the treatment in hospitalized COVID-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS).

The EMA approved teclistamab for the treatment of relapsed and refractory multiple myeloma.
 
The EMA approved eladocagene exuparvovec for the treatment of aromatic l-amino acid decarboxylase (AADC) deficiency.
 
Announced Research Updates
 
VBL Therapeutic announced that in the 409 patient, Phase III OVAL trial, adding ofranergene obadenovec to paclitaxel did not improve overall survival or progression-free survival compared to paclitaxel monotherapy in patients with platinum-resistant ovarian cancer.
 
VistaGen announced that in the Phase III PALISADE-1 trial, treatment with PH94B did not decrease the Subjective Units of Distress Scale (SUDS) compared to placebo in patients with social anxiety experiencing acute anxiety.
 
Published Research Updates
 
The 639 patient Phase III, INTELLANCE-1 trial was discontinued after an interim analysis failed to demonstrate an improvement in overall survival with depatuxizumab in combination with radiation and temozolomide in the treatment of EGFR-amplified glioblastoma.
 
In the 52-week, 346 patient, Phase III, ACOUSTICS trial, the annual exacerbation rate was decreased by 51% with lebrikizumab 125 mg and 40% with 37.5 mg compared to placebo in adolescents (aged 12-17 years) with uncontrolled asthma.
 
In the 20-week, 276 patient, Phase II METEORIC-HF trial, treatment with omecamtiv mecarbi did not improve peak oxygen uptake during cardiopulmonary exercise testing compared to placebo in patients with HFrEF.
 
In the six-week, 166 patient, Phase III FLASH trial, 16% of patients treated with one cycle of light activated topical hypericin had at least a 50% reduction in lesions compared to 4% with placebo in patients with early-stage cutaneous T-cell lymphoma. In the open-label extension of the trial, 40% of patients that received two cycles and 49% that received three cycles achieved a 50% reduction.
 
In a 12-week, 40 patient, Phase II trial, treatment with palovarotene did not reduce heterotopic ossification flare-ups compared to placebo in patients with fibrodysplasia ossificans progressiva (FOP).
 
In a 402 patient, Phase III trial, treatment with the oral combination of paclitaxel and encequidar resulted in an overall response rate of 36% compared to 23% with IV paclitaxel in patients with metastatic breast cancer.
 
In the induction phase of the 50-week, 219 patient, Phase III ultraVIOLET trial, oteseconazole was non-inferior to fluconazole (93.2% vs 95.8%) in resolving an acute vulvovaginal candidiasis (VVC) infection in female patients with recurrent VVC. 185 patients entered the maintenance phase and were treated with oteseconazole or fluconazole for 11 weeks and then followed for 37 weeks. At the end of 48-weeks, 5.1% of oteseconazole patients experienced a culture-verified acute infection compared to 42.2% with fluconazole.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.